Lv0
0 积分 2022-03-14 加入
Targeting the Pathogenesis of IgA Nephropathy — A New Treatment Approach?
10小时前
已完结
Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial
11小时前
已完结
Telitacicept Add Glucocorticoids Versus Telitacicept Alone in the Treatment of IgA Nephropathy: A Real‐World Study
28天前
已完结
Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy
1个月前
已完结
Multi-omics analyses reveal the pathogenic role of terminal ileum-derived IgA+β7+ cells in IgA nephropathy
2个月前
已完结
The Pathology of IgA Nephropathy: How Can It Inform Management?
2个月前
已完结
Emerging Biochemical and Immunologic Mechanisms in the Pathogenesis of IgA Nephropathy
2个月前
已完结
Long-term outcomes of IgA nephropathy in China
3个月前
已完结
Targeted-release budesonide in recurrent IgA nephropathy after kidney transplantation
4个月前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
6个月前
已完结
皖公网安备34019202002308
